Kirsten Craven

Want to accelerate your drug discovery workflow?

Aug 4, 2023 | Blogs, Echo MS, Pharma | 0 comments

Read Time: 2 minutes

Bringing a new drug to market is a costly and complex process. With potentially hundreds of thousands of new compounds to screen during drug discovery, sample throughput is a common bottleneck for pharmaceutical companies. So how do you overcome this barrier?

The challenges
Let’s dig a little deeper into some of the related organizational challenges. On average, the development time for a new drug is 10–15 years, and Deloitte recently reported that the average cost of approving a new pharmaceutical for clinical use rose to $2.3 billion in 2022¹. Since approximately 90% of new drug candidates fail during development, the ability to make early, informed and accurate decisions about the safety and efficacy of new leads is key to saving time, reducing costs and maximizing success.

The solution
The Echo® MS system, which can provide accurate mass spectrometry data in seconds, can help ease these challenges. Based on Acoustic Ejection Mass Spectrometry (AEMS), this system removes the need for chromatographic separation, which increases analytical speed without compromising data quality.

This free infographic explores the concepts of AEMS-based workflows, and the benefits of using this approach for efficient and rapid lead optimization of drug candidates. For example:

Analysis is up to 50x faster than traditional LC-MS
Nanoliter sample consumption allows repeated analysis of the same sample
Acoustic ejection eliminates chromatography-related issues and minimizes sample carryover
A common compound database enables you to work globally
Easy integration into existing workflows simplifies implementation

Curious to know more?
Learn more by exploring the following content, where data from the instrument is used to demonstrate what the system offers.

Rapid MS/MS analysis with Acoustic Ejection Mass Spectrometry (AEMS)

The Echo® MS system from SCIEX breaks through bottlenecks in quantitative mass spectrometry throughput. This technical note describes a rapid, chromatography-free approach to MS/MS analysis and showcases the potential of AEMS to dramatically change the field of high-throughput analysis.

High-throughput metabolite quantification for synthetic biology

This technical note shares a quantitative approach for the screening of 90 yeast strains to monitor over 60 metabolites. This workflow demonstrates the ability of the Echo® MS system to rapidly screen a biological matrix for key metabolites of interest with significantly reduced analysis times.

References

Pharma R&D return on investment falls in post-pandemic market. Deloitte, January 9, 2023. https://www2.deloitte.com/uk/en/pages/press-releases/articles/pharma-r-d-return-on-investment-falls-in-post-pandemic-market.html

Echo® and Echo® MS are trademarks or registered trademarks of Labcyte, Inc. in the United States and other countries, and are being used under license.

Understanding PFAS and its impact on U.S. drinking water

In recent years, per- and polyfluoroalkyl substances (PFAS), often referred to as “forever chemicals,” have become a growing topic of interest due to their persistence in the environment and potential health risks. These synthetic compounds have been widely used in various industrial applications and consumer products since the 1940s. PFAS can be found in the air, soil, and water, and studies have shown that most people have detectable levels of PFAS in their bloodstream. One of the main exposure pathways for humans is through drinking water, particularly in communities located near industrial sites, military bases, or areas where firefighting foam has been used.

Selecting an LC-MS system for quantitation of pharmaceutical drug development

We understand you are busy, needing to prioritize running instruments, reporting results and managing your laboratory to meet deadlines. We created a solution guide to explain how SCIEX systems fit in the drug development pipeline to save you time evaluating options.

Nitrosamines: Where are we now?

Nitrosamines are a large group of N-nitroso compounds that share a common functional N-N=O group. They are produced by a chemical reaction between a nitrosating agent and a secondary or tertiary amine. Back in 2018, nitrosamines suddenly found themselves in the spotlight when they were unexpectedly detected in medications for high blood pressure. Since then, they have been found in several other prescription medications, including those for heartburn, acid reflux and diabetes, resulting in manufacturers recalling some common medications.

Posted by

Kirsten Craven

Kirsten Craven is the Senior Global Marketing Manager for Pharma global strategic marketing at SCIEX. In this role, she manages strategic marketing for the pharmaceutical industry. Kirsten spent the first part of her career working in laboratories across multiple industries before moving into product management, and most recently pharma marketing.

0 Comments